The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review
Heart failure (HF) is one of the leading causes of morbidity and mortality worldwide. Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved for the treatment of HF. At present, there have been few systematic and detailed reviews discussing the efficacy and safety of s...
Saved in:
Main Authors: | Rui Zhang MD, PhD (Author), Xiaotong Sun PhD (Author), Ya Li MD, PhD (Author), Wenzheng He MM (Author), Hongguang Zhu MD, PhD (Author), Baoshan Liu MD, PhD (Author), Aiyuan Zhang MD, PhD (Author) |
---|---|
Format: | Book |
Published: |
SAGE Publishing,
2022-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Duration of Heart Failure With Reduced Ejection Fraction Associated With Electrocardiographic Outcomes Before and After Sacubitril/Valsartan
by: Po-Lin Lin MD, et al.
Published: (2022) -
Patient Perspectives of a Non-Invasive Telemonitoring Tool for Patients with Heart Failure
by: Motohiro Sano PhD, RN, et al.
Published: (2022) -
Predicting Hospital Readmissions in Patients Receiving Novel-Dose Sacubitril/Valsartan Therapy: A Competing-Risk, Causal Mediation Analysis
by: Changchun Hou MD, et al.
Published: (2023) -
Trends and Changes in Intensive Care Use for Patients With Heart Failure in the Last Month of Life
by: Pi-Ling Chou PhD, et al.
Published: (2024) -
Up-Titration of Sacubitril/Valsartan Among Patients With Heart Failure and Preserved Ejection Fraction
by: Koichiro Matsumura MD, et al.
Published: (2023)